BRIEF-Neuren Pharmaceuticals Informed Of Negative Trend Vote On MAA For Trofinetide

Reuters

Feb 03

BRIEF-<a href="https://laohu8.com/S/NEU.AU">Neuren Pharmaceuticals</a> Informed Of Negative Trend Vote On MAA For Trofinetide

Feb 3 (Reuters) - Neuren Pharmaceuticals NEU.AX:

WAS INFORMED OF A NEGATIVE TREND VOTE ON ITS MAA FOR TROFINETIDE
ACADIA TO REQUEST RE-EXAMINATION OF CHMP OPINION
ACADIA WAS INFORMED BY COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE OF EUROPEAN MEDICINES AGENCY

Further company coverage: NEU.AX

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608811019"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608811019\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608811019?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 08:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608811019","market":"fut","top_or_hot":-1,"title":"BRIEF-Neuren Pharmaceuticals Informed Of Negative Trend Vote On MAA For Trofinetide","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> Informed Of Negative Trend Vote On MAA For Trofinetide</title></head><body><p><span>Feb 3 (Reuters)</span><span> - </span>Neuren Pharmaceuticals <span>NEU.AX</span>:</p><ul><li><p>WAS INFORMED OF A NEGATIVE TREND VOTE ON ITS MAA FOR TROFINETIDE</p></li><li><p>ACADIA TO REQUEST RE-EXAMINATION OF CHMP OPINION</p></li><li><p>ACADIA WAS INFORMED BY COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE OF EUROPEAN MEDICINES AGENCY</p></li></ul><p>Further company coverage: <span>NEU.AX</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Neuren Pharmaceuticals Informed Of Negative Trend Vote On MAA For Trofinetide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Neuren Pharmaceuticals Informed Of Negative Trend Vote On MAA For Trofinetide\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-03 08:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> Informed Of Negative Trend Vote On MAA For Trofinetide</title></head><body><p><span>Feb 3 (Reuters)</span><span> - </span>Neuren Pharmaceuticals <span>NEU.AX</span>:</p><ul><li><p>WAS INFORMED OF A NEGATIVE TREND VOTE ON ITS MAA FOR TROFINETIDE</p></li><li><p>ACADIA TO REQUEST RE-EXAMINATION OF CHMP OPINION</p></li><li><p>ACADIA WAS INFORMED BY COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE OF EUROPEAN MEDICINES AGENCY</p></li></ul><p>Further company coverage: <span>NEU.AX</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YY1PG:1","article_id":"2608811019","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608811019","pubTimestamp":1770079483,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Neuren Pharmaceuticals Informed Of Negative Trend Vote On MAA For TrofinetideFeb 3  - Neuren Pharmaceuticals NEU.AX:WAS INFORMED OF A NEGATIVE TREND VOTE ON ITS MAA FOR TROFINETIDEACADIA TO REQUEST RE-EXAMINATION OF CHMP OPINIONACADIA WAS INFORMED BY COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE OF EUROPEAN MEDICINES AGENCYFurther company coverage: NEU.AX ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","BK7508":"医药生物股","NEU.AU":"NEUREN PHARMACEUTICALS LTD"},"translate_title":"简报-Neuren Pharmaceuticals获悉曲非奈肽MAA的负面趋势投票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":0.9},"content_text":"BRIEF-Neuren Pharmaceuticals Informed Of Negative Trend Vote On MAA For TrofinetideFeb 3 (Reuters) - Neuren Pharmaceuticals NEU.AX:WAS INFORMED OF A NEGATIVE TREND VOTE ON ITS MAA FOR TROFINETIDEACADIA TO REQUEST RE-EXAMINATION OF CHMP OPINIONACADIA WAS INFORMED BY COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE OF EUROPEAN MEDICINES AGENCYFurther company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}